[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O: Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med; 2004 Jan 15;350(3):239-48
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease associated with Campylobacter jejuni.
  • BACKGROUND: Immunoproliferative small intestinal disease (also known as alpha chain disease) is a form of lymphoma that arises in small intestinal mucosa-associated lymphoid tissue (MALT) and is associated with the expression of a monotypic truncated immunoglobulin alpha heavy chain without an associated light chain.
  • Early-stage disease responds to antibiotics, suggesting a bacterial origin.
  • METHODS: We performed polymerase chain reaction (PCR), DNA sequencing, fluorescence in situ hybridization, and immunohistochemical studies on intestinal-biopsy specimens from a series of patients with immunoproliferative small intestinal disease.
  • RESULTS: Analysis of frozen intestinal tissue obtained from an index patient with immunoproliferative small intestinal disease who had a dramatic response to antibiotics revealed the presence of Campylobacter jejuni.
  • A follow-up retrospective analysis of archival intestinal-biopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease.
  • CONCLUSIONS: These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states.
  • [MeSH-major] Campylobacter jejuni / isolation & purification. Immunoproliferative Small Intestinal Disease / microbiology
  • [MeSH-minor] Anti-Bacterial Agents. Anti-Ulcer Agents / therapeutic use. Campylobacter Infections. DNA, Bacterial / analysis. Drug Therapy, Combination / therapeutic use. Female. Genes, Immunoglobulin. Humans. Immunoglobulin A / blood. Immunoglobulin Fragments / analysis. Immunoglobulin Fragments / genetics. Immunohistochemistry. In Situ Hybridization, Fluorescence. Intestine, Small / immunology. Intestine, Small / microbiology. Intestine, Small / pathology. Middle Aged. Omeprazole / therapeutic use. Polymerase Chain Reaction. Sequence Analysis, DNA

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Massachusetts Medical Society
  • [CommentIn] Rev Gastroenterol Disord. 2005 Summer;5(3):181-2 [16156008.001]
  • [CommentIn] N Engl J Med. 2004 Apr 15;350(16):1685-6; author reply 1685-6 [15084705.001]
  • [CommentIn] N Engl J Med. 2004 Jan 15;350(3):213-5 [14724298.001]
  • (PMID = 14724303.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0 / DNA, Bacterial; 0 / Immunoglobulin A; 0 / Immunoglobulin Fragments; KG60484QX9 / Omeprazole
  •  go-up   go-down


2. Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, Child JA: Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood; 2006 Sep 15;108(6):2013-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.
  • While investigating 2592 patients enrolled in multicenter myeloma trials, we found light chain-only (LCO) patients had worse median survival times (1.9 years) than patients with IgA and IgG paraproteins (2.3 and 2.5 years, respectively) (P < .001).
  • However, IgA and IgG patients with levels of LC excretion similar to those of LCO patients also had poor survival times because of renal failure, resulting in worse survival during induction therapy and at relapse with no difference in progression-free survival between LCO and IgG patients.
  • LC excretion was higher for lambda than for kappa types, but there was no difference in survival between the 2 LC types when stratified for level of LC excretion, indicating that care of renal function is vital to improving the survival of any patient with LC excretion.
  • No differences were observed between IgA and IgG patients in presentation characteristics, response, or survival from disease progression.
  • The worse survival of IgA patients was attributed to shorter progression-free survival (median, 1.2 vs 1.6 years; P < .001), which is important for maintenance therapy.
  • [MeSH-major] Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Myeloma Proteins / metabolism
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Female. Great Britain / epidemiology. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin Heavy Chains / blood. Immunoglobulin Light Chains / blood. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728700.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Myeloma Proteins
  •  go-up   go-down


3. Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami T, Moriwaki H: Immunoproliferative small intestinal disease with protein loss complicated with duodenal T cell lymphoma during progression. Intern Med; 2008;47(4):299-303
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease with protein loss complicated with duodenal T cell lymphoma during progression.
  • A 52-year-old man was admitted to our hospital in October 2001 with abdominal pain.
  • Abdominal X-ray indicated a diagnosis of ileus.
  • Histopathological and immunological examination resulted in a diagnosis of immunoproliferative small intestinal disease (IPSID).
  • He was treated with THP-COP therapy (pirarubicin, cyclophosphamide, vincristine, and prednisolone), which resulted in complete remission.
  • He was diagnosed with relapsed IPSID and salvage chemotherapy was started.
  • Follow-up endoscopy confirmed that the therapy was effective, but uncovered another duodenal mucosal nodularity.
  • Immunohistochemical staining revealed T-cell lymphoma.
  • Chemotherapy was discontinued and the patient died in December 2004.
  • [MeSH-major] Duodenal Neoplasms / etiology. Immunoproliferative Small Intestinal Disease / complications. Lymphoma, T-Cell / etiology
  • [MeSH-minor] Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277034.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


Advertisement
4. Landolsi A, Chabchoub I, Limem S, Gharbi O, Chaafai R, Hochlef M, Fatma LB, Trimech M, Krifa A, Ajmi S, Mokni M, Hadj Hmida MB, Ahmed SB: [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases]. Bull Cancer; 2010 Apr;97(4):435-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases].
  • [Transliterated title] Les lymphomes primitifs du tube digestif (LPTD) dans le centre tunisien: étude anatomoclinique et résultats thérapeutiques à propos de 153 cas.
  • Primary gastro-intestinal lymphoma (PGIL) is the most common type of extra-nodal non Hodgkin's lymphoma.
  • Their clinical and histological presentations are heterogeneous depending on the site of the lesion.
  • There is no consensus regarding the role of surgery and chemotherapy in the therapeutic approach.
  • In our country epidemiology of the disease is unknown with IPSID being the most frequent type.
  • We report anatomo-clinical features and prognostic factors of PGIL and compare intestinal to gastric forms in our region.
  • Tumor sites were gastric (67%), intestinal (26%) and gastrointestinal (7%).
  • Abdominal pain (87%) followed by vomiting and diarrhoea (37 and 15%) were the most common symptoms.
  • Performance status (PS) < 2 was seen in 80% of patients, high grade lymphoma in 70.5% of cases and B phenotype was noted in 85%.
  • MALT lymphoma accounts for 50% of cases, and IPSID for only 5% of PGIL.
  • About 47.5% of cases were stage IE, 138 patients had chemotherapy with an objective response rate of 77%.
  • Only 46% of patients had surgery (14 for surgical complication, 6 for residual tumor after chemotherapy and 22 to have histological diagnosis).
  • In high grade lymphoma patients favorable prognostic factors for OS included young age < or = 60 years, PS < 2, normal serum LDH, hemoglobin > 12 g/dL, B phenotype, localised stage (IE-IIE1), anthracycline-based chemotherapy regimen, achieving complete or partial response to induction chemotherapy and no relapse.
  • In low-grade lymphoma patients, none of these factors had a significant correlation with OS: age < or = 60 years, PS < 2, stage (IE-IIE1), response to induction chemotherapy, relapse.
  • Compared to gastric lymphomas, intestinal cases occurred at a younger age, frequently with diarrhoea, weight loss, and occlusion.
  • We conclude that stomach is the main site of PGIL in our region, intestinal lymphoma is less frequent and IPSID has become rare.
  • Recent progress in chemotherapy has allowed good therapeutic results with a conservative approach.
  • Surgery may be performed in case of emergency or for residual lesions after medical treatment.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diarrhea / etiology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tunisia. Vomiting / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395189.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Pai RK, Snider WK, Starkey CR, Viswanatha D, Foucar MK, Wilson CS: Nonsecretory variant of immunoproliferative small intestinal disease: a case report with pathologic, immunophenotypic, and molecular findings. Arch Pathol Lab Med; 2005 Nov;129(11):1487-90
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsecretory variant of immunoproliferative small intestinal disease: a case report with pathologic, immunophenotypic, and molecular findings.
  • We report a case of the nonsecretory variant of immunoproliferative small intestinal disease involving the distal small bowel and the mesenteric and retroperitoneal lymph nodes in a 19-year-old woman from Mexico.
  • This variant extranodal marginal zone B-cell lymphoma appeared similar in the different sites of involvement, with more interspersed large cells and greater plasmacytic differentiation present in intestinal specimens.
  • Characteristic lymphoepithelial lesions and follicular colonization were seen in intestinal and lymph node sections, respectively.
  • The neoplastic B cells were cytoplasmic immunoglobulin (Ig) A heavy-chain restricted and lacked surface and cytoplasmic light-chain expression by flow cytometric analysis.
  • Molecular studies showed absence of immunoglobulin heavy-chain (IgH) gene rearrangement, with a nonfunctional clonotypic rearrangement of the kappa light-chain gene.
  • This case highlights the role for kappa light-chain gene evaluation in immunoproliferative small intestinal disease, because IgH gene rearrangement analysis is often negative.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / pathology. Lymph Nodes / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adult. Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Benzimidazoles / therapeutic use. Drug Therapy, Combination. Female. Gene Rearrangement, B-Lymphocyte, Light Chain / genetics. Humans. Immunophenotyping. Intestine, Small / pathology. Mesentery. Metronidazole / therapeutic use. Omeprazole / analogs & derivatives. Omeprazole / therapeutic use. Retroperitoneal Space. Sulfoxides / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253033.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Benzimidazoles; 0 / Sulfoxides; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; D8TST4O562 / pantoprazole; KG60484QX9 / Omeprazole
  •  go-up   go-down


6. Ghoshal UC, Chetri K, Banerjee PK, Choudhuri G, Pal BB, Dabadghao S, Dhar K, Naik S, Naik SR: Is immunoproliferative small intestinal disease uncommon in India? Trop Gastroenterol; 2001 Jan-Mar;22(1):14-7
Hazardous Substances Data Bank. TETRACYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is immunoproliferative small intestinal disease uncommon in India?
  • Till date only three series of immunoproliferative small intestinal disease (IPSID) describing 22 patients have been reported from India.
  • Seven patients with IPSID in two tertiary referral centers in India are included in the study.
  • Diagnosis was based on typical clinical features [diarrhoea (7/7), weight loss (7/7), clubbing (6/7), fever (3/7), abdominal pain and lump (3/7)], biochemical evidence of malabsorption and duodenal biopsy findings.
  • Atypical features included gastric involvement (1/7), colonic involvement (1/7) and appearance of pigmented nails following anti-cancer chemotherapy (1/7) which disappeared six months after omitting doxorubin from chemotherapy regimen.
  • In the latter patient S. stercoralis became disseminated after anti-malignant chemotherapy.
  • This raises doubt on efficacy of tetracycline alone in treatment of IPSID.
  • One other patient was misdiagnosed and treated as intestinal tuberculosis.
  • Early diagnosis and administration of chemotherapy may improve survival in this disease.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. India / epidemiology. Middle Aged. Prednisolone / therapeutic use. Prognosis. Tetracycline / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11398237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; F8VB5M810T / Tetracycline; VAP-cyclo protocol
  •  go-up   go-down


7. Dutta U, Udawat H, Noor MT, Sidhu GS, Kochhar R, Vaiphei K, Singh K: Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. J Gastrointest Cancer; 2010 Sep;41(3):212-5
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
  • A 20-year-old male presented with low-grade fever, abdominal pain, anorexia, and weight loss of 4-month duration.
  • Contrast-enhanced computed tomography of the abdomen revealed extensive proximal small-bowel thickening with mesenteric lymphadenopathy.
  • Upper gastrointestinal endoscopy and enteroscopy revealed thickening of folds with multiple small superficial ulceration involving antrum, duodenum, and jejunum.
  • The duodenal and jejunal biopsy was suggestive of immunoproliferative small intestinal disease, stage 0 (Salem) or stage A (Galian).
  • He underwent H. pylori eradication following which he had significant clinical improvement; repeat evaluation at 6 months showed dramatic improvement in his clinical, radiological, and histological parameters.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Helicobacter Infections / complications. Immunoproliferative Small Intestinal Disease / drug therapy. Immunoproliferative Small Intestinal Disease / microbiology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Amoxicillin / therapeutic use. Clarithromycin / therapeutic use. Doxycycline / therapeutic use. Drug Therapy, Combination. Helicobacter pylori. Humans. Lansoprazole. Male. Omeprazole / therapeutic use. Organometallic Compounds / therapeutic use. Tinidazole / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. TINIDAZOLE .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Am J Med. 1990 Oct;89(4):483-90 [2145762.001]
  • [Cites] Indian J Cancer. 1983 Nov-Dec;20(5):261-7 [6439623.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):8-14 [9210703.001]
  • [Cites] Lab Invest. 1970 May;22(5):448-57 [4911977.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Bull World Health Organ. 1976;54(6):615-24 [829415.001]
  • [Cites] Clin Gastroenterol. 1983 Sep;12(3):743-66 [6413104.001]
  • [Cites] Lancet. 1996 Jul 27;348(9022):268-9 [8684218.001]
  • [Cites] Lancet. 1997 Jan 4;349(9044):31-2 [8988128.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2274-80 [15542584.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Gut. 1979 Mar;20(3):226-8 [108183.001]
  • (PMID = 20300878.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Organometallic Compounds; 033KF7V46H / Tinidazole; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; HS813P8QPX / bismuth tripotassium dicitrate; KG60484QX9 / Omeprazole; N12000U13O / Doxycycline
  •  go-up   go-down


8. Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabeçadas J, Dong HY, Harris NL, Chan JK, Rees JW, Dogan A, Isaacson PG: KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood; 2002 Nov 1;100(9):3415-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV- and EBV-associated germinotropic lymphoproliferative disorder.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with 3 distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablastic lymphoma.
  • We report 3 cases of a previously undescribed KSHV-associated lymphoproliferative disorder.
  • The disease presented as localized lymphadenopathy and showed a favorable response to chemotherapy or radiotherapy.
  • They were negative for CD20, CD27, CD79a, CD138, BCL6, and CD10 but showed monotypic kappa or lambda light chain.
  • Unexpectedly, molecular analysis of whole tissue sections or microdissected KSHV-positive aggregates demonstrated a polyclonal or oligoclonal pattern of immunoglobulin (Ig) gene rearrangement.
  • The plasmablasts showed somatic mutation and intraclonal variation in the rearranged Ig genes, and one case expressed switched Ig heavy chain (IgA), suggesting that they originated from germinal center B cells.
  • We propose calling this distinctive entity "KSHV-associated germinotropic lymphoproliferative disorder. "
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Clone Cells / chemistry. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / drug therapy. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / radiotherapy. Epstein-Barr Virus Infections / virology. Female. Gene Rearrangement, B-Lymphocyte. Germinal Center / pathology. Humans. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Immunophenotyping. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12384445.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Ramaiah SK, Seguin MA, Carwile HF, Raskin RE: Biclonal gammopathy associated with immunoglobulin A in a dog with multiple myeloma. Vet Clin Pathol; 2002;31(2):83-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma was diagnosed based on bone marrow plasmacytosis, multiple lytic bone lesions, and hyperglobulinemia with a clonal gammopathy on serum protein electrophoresis.
  • Temporary responses to 2 different chemotherapy protocols (melphalan and prednisone, and cyclophosphamide and prednisone) were seen, with remission of clinical signs and a decrease in the biclonal gammopathy but no resolution of the splenic mass.
  • Eventual return of clinical signs led to euthanasia at 175 days postdiagnosis.
  • An immunoglobulin-A (IgA) gammopathy was demonstrated by immunoelectrophoresis; biclonality was ascertained by immunofixation electrophoresis.
  • The clonal components consisted of intact Ig with heavy chain of the alpha class and light chain of an undetermined class.
  • To our knowledge, this is the first report of undimerized biclonal gammopathy in a dog caused by a single heavy chain class involving IgA.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12040490.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


10. Economidou I, Manousos ON, Triantafillidis JK, Vaslamatzis MM, Zafiropoulou R, Papadakis T: Immunoproliferative small intestinal disease in Greece: presentation of 13 cases including two from Albania. Eur J Gastroenterol Hepatol; 2006 Sep;18(9):1029-38
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease in Greece: presentation of 13 cases including two from Albania.
  • OBJECTIVES: Immunoproliferative small intestinal disease (IPSID) represents a spectrum of clinicopathological entities including alpha-chain disease and other types of lymphoplasmacytic proliferations of the lamina propria of the small intestine, presenting with severe malabsorption.
  • IPSID has been described mainly in the Mediterranean, Middle East, and African countries.
  • METHODS: Current immunological and immunohistochemical methods for the detection of alpha heavy chains and the presence of clonality have been used to study 13 cases of IPSID diagnosed in Greece, two of whom were Albanian residents.
  • RESULTS: The patients were categorized in three subgroups of IPSID: alpha-chain disease (n=8), non-alpha chain disease with other monoclonal immunoglobulins (n=3), and polyclonal 'non-malignant' IPSID (n=2).
  • In several patients the disease had unusual features, and this in some cases delayed the diagnosis.
  • Patients with stage C disease had a short survival, whereas two patients with stage A alpha-chain disease responded to treatment with cyclophosphamide, vincristine and prednisolone, and cyclophosphamide, doxorubicine, vincristine and prednisolone, respectively, have a disease-free long survival of 35 and 12 years, and appear to be cured.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / diagnosis
  • [MeSH-minor] Adult. Albania. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Therapy, Combination. Female. Greece. Humans. Male. Middle Aged. Prednisolone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894320.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


11. Witzig TE, Wahner-Roedler DL: Heavy chain disease. Curr Treat Options Oncol; 2002 Jun;3(3):247-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heavy chain disease.
  • The heavy chain diseases (HCDs) are rare B-cell malignancies that are distinguished by the production of a monoclonal immunoglobulin heavy chain (HC) without an associated light chain by the malignant B-cells.
  • There are three types of HCD defined by the class of immunoglobulin (Ig) HC produced: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD).
  • Alpha-HCD is the most common and occurs most commonly as intestinal malabsorption in a young adult from a country bordering the Mediterranean Sea.
  • Treatment consists of antibiotics and improved nutrition and hygiene.
  • If there is no response to antibiotics or if aggressive non-Hodgkin's lymphoma (NHL) is diagnosed, the patient should be treated with chemotherapy.
  • Gamma- and mu-HCD are rare and essentially are found in patients with a B-cell NHL that produces an abnormal Ig heavy chain.
  • These patients occasionally may be diagnosed with a monoclonal gammopathy of undetermined significance (MGUS).
  • Patients with MGUS with NHL should be administered chemotherapy.
  • Screening the serum and urine of patients with lymphoplasmacytoid NHL would likely identify more patients with gamma- or mu-HCD.
  • [MeSH-major] Heavy Chain Disease / therapy
  • [MeSH-minor] Adult. Aged. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Incidence. Middle Aged. Radiotherapy

  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for heavy chain disease .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Rheumatol. 2000 Jan;12(1):65-70 [10647957.001]
  • [Cites] Histopathology. 1990 Jul;17(1):7-17 [2227833.001]
  • [Cites] J Clin Gastroenterol. 1998 Jul;27(1):85-9 [9706780.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):231-4 [9858149.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):359-65 [9401282.001]
  • [Cites] Rev Prat. 1993 Feb 1;43(3):317-20 [8502962.001]
  • [Cites] Mayo Clin Proc. 1987 Aug;62(8):719-31 [3110508.001]
  • [Cites] Clin Chem. 1994 Apr;40(4):664 [8149622.001]
  • [Cites] Arch Pathol Lab Med. 1986 Oct;110(10):893-6 [3094476.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Eur J Haematol. 1995 Mar;54(3):202-4 [7720844.001]
  • [Cites] J Am Acad Dermatol. 1990 Nov;23(5 Pt 2):988-91 [2121807.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):18-22 [8554029.001]
  • [Cites] Am J Med. 1990 Oct;89(4):483-90 [2145762.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):737-42 [10792277.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):653-5 [7819086.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):8-14 [9210703.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Gastroenterol Clin Biol. 1985 Jun-Jul;9(6-7):472-9 [3926586.001]
  • [Cites] Hum Pathol. 1984 Feb;15(2):122-9 [6421714.001]
  • [Cites] Am J Hematol. 1992 May;40(1):56-60 [1566748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2463-8 [9482908.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):427-36 [6814232.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):400-6 [7674998.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1375-82 [8021727.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1281-94 [10626151.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Z Gastroenterol. 1995 Apr;33(4):209-13 [7793120.001]
  • [Cites] Clin Chem. 1981 Feb;27(2):331-3 [7460288.001]
  • [Cites] Mayo Clin Proc. 1981 Jul;56(7):439-51 [6789012.001]
  • [Cites] Recent Results Cancer Res. 1978;64:271-6 [104370.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1251-6 [2920354.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Gut. 1978 Jul;19(7):627-31 [98395.001]
  • (PMID = 12057070.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 36
  •  go-up   go-down


12. Cagnoli L, Italian Society of Nephrology: [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties]. G Ital Nefrol; 2003 Sep-Oct;20 Suppl 24:S3-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
  • [Transliterated title] Linee Guida sulle indicazioni ed esecuzione della biopsia renale percutanea e sulla terapia delle nefropatie glomerulari.
  • Each author was asked to review the literature for his assigned histological type, with emphasis on therapy and limited to adult studies.
  • The age limit was not considered for minimal change disease and focal segmental glomerulosclerosis, because of the high prevalence of these glomerulopathies in children.
  • The particular treatment recommendations for each type of glomerular disease were graded by each author according to the amount of evidence provided in these reviewed studies.
  • Each subsequent article focuses on and describes the highest level of evidence supporting the recommendation for therapy in IgA nephropathy (Ig-GN), minimal change nephropathy (MCN) and focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), lupus nephritis, ANCA-associated vasculitis, HCV-associated cryoglobulinaemia and renal involvement in paraproteinemic disorders.
  • The article on IgA nephropathy emphasises the importance of carefully evaluating both clinical and histologic findings before settling on the treatment.
  • For both of these diseases, in fact, the initial treatment approach in children should be prednisone or prednisolone for four to six weeks.
  • The therapeutic response in adults is slower than in children, but adults experience fewer relapses and a more prolonged remission.
  • There is also a discussion on treatment of relapse, frequent relapsing disease and true steroid-resistant disease as well as the role of new immunosuppressive agents.
  • Membranous nephropathy is a frequent cause of nephrotic syndrome in adults and, in one third of these patients, leads to end-stage renal disease.
  • However, the treatment of this form is as yet a matter of discussion.
  • Based on extensive critical review of the literature, the following recommendations are put forward: (a) no treatment in the absence of nephrotic syndrome;.
  • (b) patients with heavy proteinuria should receive a 6-month treatment with i.v. methylprednisolone (MP) pulse therapy for three consecutive days followed by oral MP (0.4 mg/kg/day) (months 1, 3, 5) and chlorambucil or cyclophosphamide (months 2, 4, 6);.
  • (d) cyclosporine is a second-choice treatment.
  • The treatment of lupus nephritis depends on the histologic class.
  • No specific treatment is usually necessary for class I and IIA.
  • Oral steroids are indicated in patients with class IIb, proteinuria and active systemic disease.
  • Steroids and azathioprine are the treatment of choice for patients with class III and IV, but cyclosporine can be an effective alternative therapy.
  • The treatment of ANCA-associated vasculitis depends mainly on clinical presentation, oral prednisone + oral or i.v. cyclophosphamide are generally effective.
  • In the most severe cases, the association of MP pulse therapy with cyclophosphamide is probably more effective.
  • Azathioprine should replace cyclophosphamide during the maintenance therapy.
  • In HCV-associated mixed cryoglobulinemia the treatment also depends on the severity of renal involvement.
  • The treatment for chronic HCV infection involves alpha interferon alone or preferably in combination with ribavirin.
  • Aggressive therapy, including i.v.
  • MP, plasmapheresis and cyclophosphamide is primarily reserved for patients with acute severe disease, as manifested by progressive renal failure, distal necroses requiring amputation, or advanced neuropathy.
  • The most common renal diseases in this setting are cast nephropathy, primary amyloidosis cast nephropathy, primary amyloidosis, and light chain deposition disease that are related to the overproduction of monoclonal immunoglobulin light chains.
  • The approach to therapy varies with the cause of the renal dysfunction.
  • Patients with amyloidosis or light-chain deposition disease are generally treated with chemotherapy, but the most effective therapy for myeloma kidney is prevention by minimising the risk factors that promote light chain filtration and subsequent obstruction by cast formation within the tubules.
  • Chemotherapy or stem cell or bone marrow transplantation to decrease filtered light chain load, prevent volume depletion and maintain high fluid intake to reduce light chain concentration within the tubular lumen are indicated in almost all the patients.
  • [MeSH-major] Biopsy / methods. Glomerular Mesangium. Kidney / pathology. Kidney Diseases / pathology. Kidney Diseases / therapy
  • [MeSH-minor] Glomerulonephritis / drug therapy. Glomerulonephritis / metabolism. Humans. Immunoglobulin A / metabolism

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666502.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin A
  • [Number-of-references] 534
  •  go-up   go-down


13. Ben Ammar A, Cheikh I, Jouini M, Belkahla N, Fadhel SF, Hager O, Maamouri N, Chaabouni H, Ben Safta Z, Haouet S: [Alpha heavy chain disease. A Tunisian case]. Tunis Med; 2006 Sep;84(9):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alpha heavy chain disease. A Tunisian case].
  • [Transliterated title] Maladie des chaines lourdes alpha. A propos d'un cas tunisien.
  • Alpha heavy chain disease is a rare affection in the West and reported mainly in developing countries with the improvement of hygienic conditions, the disease become rare in Tunisia, the last case was reported in 1991.
  • The aim of the study is to report a new Tunisian case and to describe clinical, endoscopical and histological characteristics of the disease.
  • The diagnosis of alpha heavy chain disease was confirmed by histological examination of the resected intestine after surgery for intestinal obstruction.
  • The patient received chemotherapy.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / diagnosis
  • [MeSH-minor] Adult. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263208.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


14. Ramadeen A, Laurent G, dos Santos CC, Hu X, Connelly KA, Holub BJ, Mangat I, Dorian P: n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm; 2010 Apr;7(4):520-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to use a genome-wide approach to identify gene expression profiles involved in a new model of AF vulnerability and to determine whether they were altered by PUFA therapy.
  • Atrial tissue was sampled at the end of the protocol.
  • Results were confirmed with quantitative real-time polymerase chain reaction (RT-PCR) and histology on all 36 dogs.
  • RESULTS: Microarray or quantitative RT-PCR results showed that SAVP-No PUFAs dogs had significantly increased mRNA levels of protein kinase B (Akt), epidermal growth factor (EGF), JAM3, myosin heavy chain alpha (MHCalpha), and CD99 and significantly decreased levels of Smad6 compared with CTRL dogs.
  • [MeSH-major] Atrial Fibrillation / prevention & control. Atrial Function / drug effects. Cardiomyopathies / genetics. Cardiovascular Agents / pharmacology. Fatty Acids, Omega-3 / pharmacology. Heart Atria / drug effects
  • [MeSH-minor] Animals. Disease Models, Animal. Dogs. Fibrosis / genetics. Gene Expression / drug effects. Hypertrophy / genetics. Stress, Mechanical


15. Khositseth S, Kanitsap N, Warnnissorn N, Thongboonkerd V: IgA nephropathy associated with Hodgkin's disease in children: a case report, literature review and urinary proteome analysis. Pediatr Nephrol; 2007 Apr;22(4):541-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgA nephropathy associated with Hodgkin's disease in children: a case report, literature review and urinary proteome analysis.
  • We report herein a rare case of IgAN associated with Hodgkin's disease in a 14-year-old boy.
  • Clinical manifestations and laboratory parameters were improved after treatment with CHOP chemotherapy and enalapril.
  • Urinary proteins were isolated and examined using state-of-the-art proteomic technology, before and during the treatment course.
  • Two-dimensional gel electrophoresis showed obvious alterations in the urinary proteome profile in response to such therapy.
  • Quantitative intensity analysis and gel mapping revealed 14 altered proteins with reduced excretion levels during the treatment course, including albumin, albumin complexed with decanoic acid, alpha-1 antitrypsin, cadherin-11 precursor, collagen alpha 1 (VI) chain precursor, complement C1q tumor necrosis factor-related protein, Ig heavy chain, Ig light chain, kininogen, inter-alpha-trypsin inhibitor (alpha-1 microglobulin), inter-alpha-trypsin inhibitor heavy chain, leucine-rich alpha-2 glycoprotein, beta-2 microglobulin, and transferrin precursor.
  • [MeSH-major] Biomarkers / metabolism. Glomerulonephritis, IGA / complications. Hodgkin Disease / complications. Proteins / metabolism. Proteome / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pneumologie. 1996 Jul;50(7):494-5 [8927608.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jan;16(1):187-8 [11209025.001]
  • [Cites] Nephrol Dial Transplant. 2001 Aug;16(8):1722-3 [11477188.001]
  • [Cites] Arch Pathol Lab Med. 1978 Oct;102(10):527-9 [581342.001]
  • [Cites] J Proteome Res. 2006 Jan;5(1):183-91 [16396510.001]
  • [Cites] Turk J Pediatr. 2000 Apr-Jun;42(2):109-14 [10936975.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1159-74 [15048996.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2648-55 [15984045.001]
  • [Cites] Am J Kidney Dis. 2002 Mar;39(3):469-74 [11877565.001]
  • [Cites] Am J Kidney Dis. 2005 Jan;45(1):e16-9 [15696435.001]
  • [Cites] Med Klin (Munich). 1997 Dec 15;92(12):712-9 [9483914.001]
  • [Cites] Kidney Int. 1977 May;11(5):297-303 [197291.001]
  • [Cites] Proteomics. 2004 Nov;4(11):3485-97 [15529407.001]
  • [Cites] Am J Kidney Dis. 1993 May;21(5):545-7 [8488823.001]
  • [Cites] Clin Nephrol. 2005 Nov;64(5):329-36 [16312259.001]
  • [Cites] Kidney Int. 1986 Oct;30(4):465-73 [3537450.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2337-46 [14633607.001]
  • [Cites] Contrib Nephrol. 1984;40:283-91 [6499458.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1461-9 [12234320.001]
  • [Cites] J Am Soc Nephrol. 2005 Jul;16(7):2088-97 [15930092.001]
  • [Cites] Scand J Urol Nephrol. 1998 Feb;32(1):61-3 [9561579.001]
  • [Cites] Nephrol Dial Transplant. 1991;6(3):155-8 [1866042.001]
  • [Cites] Postgrad Med J. 1988 Nov;64(757):881-2 [3255939.001]
  • [Cites] Am J Nephrol. 1983 Jul-Aug;3(4):228-32 [6688503.001]
  • [Cites] Contrib Nephrol. 2004;141:292-307 [14650240.001]
  • [Cites] J Clin Lab Anal. 2005;19(1):16-21 [15645467.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jan;14(1):179-80 [10052501.001]
  • [Cites] Nephron. 1999 Jun;82(2):127-30 [10364704.001]
  • (PMID = 17143626.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proteins; 0 / Proteome
  •  go-up   go-down


16. Celik AF, Pamuk GE, Pamuk ON, Uzunismail H, Oktay E, Doğusoy G: Should we suppress the antigenic stimulus in IPSID for lifelong? Am J Gastroenterol; 2000 Nov;95(11):3318-20
Hazardous Substances Data Bank. TETRACYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should we suppress the antigenic stimulus in IPSID for lifelong?
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Immunoproliferative Small Intestinal Disease / drug therapy. Immunoproliferative Small Intestinal Disease / immunology. Tetracycline / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11095373.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; F8VB5M810T / Tetracycline; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Xu SQ, Fang F, Zhou H: [Immunoproliferative small intestinal disease: a case report and literature review]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug;9(4):389-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoproliferative small intestinal disease: a case report and literature review].
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706052.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down






Advertisement